Recombinant Anti-CD3 x Anti-HIV-1 gp41 VHH BispecificAntibody (IgG-VHH) (IGVHH-025)

Recombinant Anti-CD3 x Anti-HIV-1 gp41 Bispecific Antibody (IgG-VHH) is designed to be expressed as a LC and an extended HC with VHH moiety linked to the C terminus. It is a symmetric bispecific and tetravalent molecule, bivalent for each antigen specificity, 2+2 antigen-binding valency. This BsAb can retarget T cells to HIV-1 infected cells. It is designed for the research of HIV-1 infection, AIDS therapy.

Datasheet INQUIRY

Specifications

Targets

CD3 & HIV-1 gp41

Type

Appended IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

HIV-1 infection, AIDS

Targets

Target 1

CD3

Gene ID

916

UniProt ID

P07766

Alternative Names

CD3; CD3E; CD3e molecule; Cluster of differentiation 3; CD3e molecule, epsilon (CD3-TCR complex); T3E; TCRE; IMD18; T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell antigen receptor complex, epsilon subunit of T3

Target 2

HIV-1 gp41

Gene ID

155971

UniProt ID

Q0H5Z9

Alternative Names

ENV; gp160; Envelope glycoprotein 120; envelope glycoprotein; Envelope surface glycoprotein gp160, precursor; hypothetical protein; Envelope surface glycoprotein gp120; Envelope transmembrane domain; human immunodeficiency virus type 1; human immunodeficiency virus type 1 gp120; human immunodeficiency virus type 1 glycoprotein 120; gp41; GP41; glycoprotein 41

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD3 x Anti-HIV-1 gp41 VHH BispecificAntibody (IgG-VHH) (IGVHH-025). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CD3 x Anti-HIV-1 gp41 VHH BispecificAntibody (IgG-VHH) (CAT#: IGVHH-025)

Specifications

Targets

Customer Reviews and Q&As